Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
about
Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settingsThe lifetime medical cost savings from preventing HIV in the United States.Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease.
P2860
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cost-effectiveness of adding a ...... guidance for drug development.
@ast
Cost-effectiveness of adding a ...... guidance for drug development.
@en
type
label
Cost-effectiveness of adding a ...... guidance for drug development.
@ast
Cost-effectiveness of adding a ...... guidance for drug development.
@en
prefLabel
Cost-effectiveness of adding a ...... guidance for drug development.
@ast
Cost-effectiveness of adding a ...... guidance for drug development.
@en
P2093
P2860
P356
P1433
P1476
Cost-effectiveness of adding a ...... guidance for drug development.
@en
P2093
Bethany L Morris
Bruce R Schackman
Callie A Scott
Paul E Sax
Roy M Gulick
Timothy J Wilkin
P2860
P356
10.1310/HCT1301-001
P577
2012-01-01T00:00:00Z